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Abstract History of cancer disease models clearly illus-
trates the evolving nature of these concepts. Since such
models undergo continual revisions and additions as a result
of underlying medical research, they also tend to reorganize
knowledge and allow perceiving previously unseen relation-
ships. Growth of medical thought has been influenced for
many centuries by an ancient Hippocratic concept of disease
seen as a disturbance in bodily “humors.” True mechanisms
of cell and tissue injury started to be elucidated only with the
advent of postmortem pathological findings. Concerning
cancer, when first disease-producing bacteria were identi-
fied in the nineteenth century, also neoplasms were treated
as infectious diseases. Foreign organisms were thought to be
present inside tumors. However, this hypothesis could not
be confirmed by microscopic or histochemical studies. The
latter suggested, instead, that tumors were rather formed by
abnormal cells. Cancer was then started to be regarded as a
disease of cells. This interpretation was radically altered by
later developments in genetics which suggested that neo-
plasms can be treated as genetic diseases as pathologic
cellular lesions are caused by mutations in specific genes.
More recent models have compared carcinogenesis to evo-
lutionary processes. Due to genetic instability, successive
mutations, appearing in cells, lead to selection of cancer
cells which feature specific phenotypic traits. The newest
data indicate that there may be also a link between cancer
and mutated stem cells. The review discusses main concepts
of tumor origin forwarded since the beginnings of the
nineteenth century.
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Introduction
Theoretical models, in general, facilitate analysis and inter-
pretation of collected data. Such models do not describe
studied processes directly, but instead, they help ordering
the gained knowledge. They often suggest novel interpreta-
tions of gathered data and help perceiving unknown relation-
ships. Owing to such models, it is easier to plan experiments
and evaluate their results [1].
Cancer development and progression is a multistep process
of truly great complexity. However, thanks to a continuous
feedback between advances in technology and proposed can-
cer theories, the factual knowledge about the nature of these
diseases has been continually expanding. The review focuses
on the most important models of carcinogenesis advanced
within the past 200 years.
From humoral disease to the disease of organs
For long centuries, medicine has been dominated by ideas
first advanced by Hippocrates and then undertaken by
Galen. These ancient physicians thought that the human
body was filled with four basic substances called humors,
i.e., blood (sanguis), yellow bile (chole) black bile (melan
chole), and phlegm (phlegm). All diseases and disabilities
resulted from an excess or deficiency of one of these four
substances. The root cause of cancer was seen in the surplus
of black bile in the body. The humoral theory became the
most commonly held view of the human body until the
onset of medical research. It has been progressively eroding
only since modern times [2].
I. Mitrus (*) : E. Bryndza :A. Sochanik : S. Szala
Center for Translational Research and Molecular Biology
of Cancer, Maria Skłodowska-Curie Memorial Cancer Center
and Institute of Oncology,
Gliwice Branch, Wybrzeze Armii Krajowej 15,
44-101 Gliwice, Poland
e-mail: mitrus@io.gliwice.pl
Tumor Biol. (2012) 33:911–917
DOI 10.1007/s13277-012-0389-0
Paracelsus has suggested (in sixteenth century) that re-
sponsible for the rise of tumors is the accumulation of harmful
substances in the bloodstream (nowadays, this is believed to
have been the first suggestion of a link between cancer and
exposure to chemical agents). A century later, a new specula-
tion, harking back to melancholism, was put forward. It held
that tumor development is caused by coagulation and fermen-
tation of blood or lymph. With time, possible causes of cancer
begun, including chronic inflammation and injuries as well as
familial predispositions and traumas [3].
The development of true medical knowledge was strong-
ly influenced by pathologists performing postmortems.
Among the first men attaching a right measure of impor-
tance to these findings was a famous Italian anatomist,
Giovanni Battista Morgagni. In 1761, he published a famous
treatise (De Sedibus et Causis Morborum per Anatomem
Indagatis) which characterized the course of various dis-
eases and linked their symptoms with subsequent autopsy
findings [2]. Morgagni believed that causes of a disease (not
only cancer) involved pathological lesions of a particular
organ. Autopsies thus contributed to the abandonment of
humoral theory in favor of perceiving disease as an “organ
lesion.” Gross pathology evolved rapidly in the nineteenth
century, owing largely to the works of an eminent Vienna-
based physician Rokitansky who is said to have performed
some 20,000 autopsies in his lifetime [4].
Fast advances in gross pathology were matched by those
in microscopic pathology as the nineteenth century saw a
more widespread use of microscopes. First, such instru-
ments were constructed toward the end of sixteenth century.
Some 50 years later, Hook described, using one of them,
structures found in biological material and termed them
“cells.” It is van Leeuwenhoek (seventeenth century), how-
ever, who is thought to have been the father of microscopy
and who described microorganisms which he called “ani-
malcules” [5]. Manufacture of an achromatic lens, in 1830,
allowed constructing microscopes with greater magnifying
power [6], which soon led to great advances in bacteriology
and cellular-level pathology.
Cancer as a parasitic disease
Until nineteenth century, no one realized the importance of
microorganisms in the disease process. Halfway into that
century, though, thanks to the works of Pasteur and Koch,
the relationship between bacterial infection and disease was
recognized [7].
Discovery of disease-causing bacteria has started a quest
for cancer “germs” in the late nineteenth century. It was
believed that the growth of tumors might be caused by
foreign organisms (bacteria, fungi, or roundworms) living
within such tumors. Toxins released by them were supposed
to emaciate the host. Metastasis was explained as parasites
attacking consecutive organs. Observed increased cancer
frequency among some families was explained as the effect
of more frequent contact (either cross infection or exposure
to the same parasite) between related individuals [8].
Attempts to isolate cancer germs were undertaken numer-
ous times. The best-known (and honored by Nobel Prize)
attempts were described by Fibiger. He studied stomach
tumors in rats fed with cockroaches infected by Spiroptera
neoplastica worm. The origin of these artifacts remains
unknown. It is likely that Fibiger mistook tumors with other
parasite-caused pathological lesions [9].
Cancer as a disease of cells
Techniques of preparing histological specimens (frozen and
fixed sections), as well as staining of biological material,
were introduced in the mid-nineteenth century. Fixing tis-
sues with paraffin was invented by Klebs in 1869, whereas
formalin was introduced into laboratory practice by Blum in
1894. Besides, dyes like carmine, extracted from cochineal
and already used by van Leeuwenhoek, new ones were
added (picric acid, basic fuchsin, eosin, and hematoxylin).
Double-staining methods (hematoxylin and eosin (H&E))
were introduced [10, 11]. These dyes not only permitted
intense development of bacteriology, but they also allowed a
more precise description of tissue and cellular structures [4].
Structure of tumors was described in greater detail. In the
first half of the nineteenth century, several researchers ob-
served that neoplastic tumors are made up of cells with
abnormal morphology. Such findings were reported by
Schleiden and Müller (in 1838) and Schwann (in 1839)
[12]. Excessive number of dividing cells, anomalous mito-
ses, oversized cell nuclei, and loss of differentiation were all
listed as characteristic features of neoplastic tumors. Other
features, such as tumor stroma, vasculature, and necrosis seen
in central part of tumors, were also noticed [8]. Toward late
nineteenth century, more and more researchers gravitated
toward the theory proposed by R. Virchow, i.e., that the
underlying cause of the disease lies in cellular lesions.
Thus, cancer started to be treated as a disorder of abnor-
mally dividing cells. They were thought to form aggregates
that mechanically damaged neighboring tissues. Furthermore,
cancer cells used up nutrients and poisoned the organism with
toxins [8]. Because of this, some researchers were considering
cancer cells as a peculiar kind of “parasite.”
Appearance of metastases was seen as a result of detach-
ment of cancer cells from tumor mass. Such cells circulated
in blood vasculature until they became trapped in distant
sites. The role of lymphatic vessels in metastasis was de-
scribed by Brouns in 1847 [13]. A theory of “seed and soil,”
credited by some to Paget, was put forward in 1889.
912 Tumor Biol. (2012) 33:911–917
According to this theory, cells (“seed”) detached from tumor
mass must find a suitable place (“soil”) in the body in order
to continue growth. The necessity of finding appropriate soil
would explain why particular types of cancer metastasize
into specific locations [13, 14].
The origin of neoplastic cells was unknown. Cohenheim
postulated that these cells could be actually embryonic cells
that were not eliminated during ontogenesis. Hanseman be-
lieved that they could be cells that underwent dedifferentiation
(anaplasia). It was even posited that cancer cells could origi-
nate from a different organism; they somehow managed to
penetrate the body of a diseased individual (Kelling). Irre-
spective of origin issue, it was conceded that uncontrolled
divisions began as a result of external physical and chemical
stimuli (burn, X-rays, or certain chemicals) [8, 12].
Cancer as a disease of genes
Treating cancer as a disease of cells brought up the question:
what is the cause of abnormal proliferation of cancer cells?
Inappropriate number of chromosomes or their incorrect
structure was often observed when studying cancer cells.
Examination of chromosomes started in the mid-nineteenth
century, even before their role in heredity was established.
At the beginning of twentieth century, Boveri hypothesized
that carcinogenesis is triggered by chromosomal aberrations
in cells. In 1910, Johannsen proposed the term “gene”
instead of “hereditary factor.” It was only in 1926 that
Muller demonstrated the mutagenic effect of X-rays, al-
though de Vries suggested the existence of mutations al-
ready in 1901. In the 1940s of the last century, chromosomal
DNA, not protein, was shown to be the carrier of genetic
information. In 1953, Watson and Crick [15] described the
structure of DNA. Within the last 50 years or so, semicon-
servative character of DNA replication was proven [16],
genetic code was learned (Holley, Khorana, Nirenberg)
[17], and finally, in the 1970s, DNA cloning and sequencing
techniques emerged.
Development of genetics had immense impact on the un-
derstanding of cancer causes. In the 1960s of the last century,
it was learned that cancer development is linked to errors
contained in the genetic material and that these errors are
transferred to progeny cells during subsequent divisions
[18]. Thus, interpretation of carcinogenesis shifted from cel-
lular (disease of cells) to molecular level (disease of genes).
At the turn of the 1970s and 1980s, a new model of
cancer disease was proposed. Accordingly, the disease
started from a single cell in which a mutation occurred.
Such cell divided under the influence of proliferation-
stimulating factors (e.g., growth factors, hormones), form-
ing a population of similar cells (clone). Tumor progression
was caused by subsequent mutations occurring in cells,
forming the clone. Clones differing from each other appeared.
Some clones might undergo growth factor-independent pro-
liferation and this triggered rapid acceleration of tumor
growth. Since no key carcinogenic genes were known, the
proposed model could only describe phenotypic cell altera-
tions and not specific mutations [19].
Search for factors increasing the risk of cancer develop-
ment has been ongoing since the nineteenth century. As far
back as in mid-eighteenth century, Hill noticed increased
frequency of cancer in smokers. In turn, Pott described fre-
quent occurrence of certain type of cancer in chimney
sweepers, which he explained to be the result of their exposure
to harmful substances present in sooth (including sulfur and
arsenic) [20]. With time elapsed, other agents were added to
this list (certain chemicals, e.g., pitch and X-rays) [8].
The mechanism of carcinogenic action has long remained
totally unknown. Explaining it became possible only with
the advent of knowledge about DNA structure. In the late
1960s of the twentieth century, it was demonstrated that
certain carcinogens have the ability to bind DNA. Genotoxic
compounds damage DNA (e.g., by forming adducts or caus-
ing DNA strand breaks). It has been known now that certain
carcinogens do not act on DNA directly; instead, they in-
duce free radicals or activate signaling pathways leading to
increased proliferation or inhibition of apoptosis [20].
A separate category of carcinogens is that formed by
viruses. In 1907, Ciuffo demonstrated that an infectious
agent responsible for human warts is transferred by cell-
free filtrates. He could not identify the pathogen, though. At
the beginning of twentieth century, it was noticed that
chicken leukemia is infectious. However, the attempts to
isolate the responsible pathogen proved futile (it was actu-
ally avian leukemia virus), and leukemia was not treated as
cancer at that time. In 1911, Rous conducted some experi-
ments during which he injected chickens with cell-free
sarcoma extract which led to the development of cancer.
Rous thus became the discoverer of the first oncogenic
virus; it was termed Rous sarcoma virus (RSV). In the
1930s of the previous century, subsequent animal cancer-
causing viruses were discovered. In the early 1960s, rela-
tionship was demonstrated between Epstein–Barr virus in-
fection and Burkitt lymphoma in humans. The earlier
mentioned observation made by Ciuffo was explained in
the 1970s; the responsible pathogen turned out to be human
papilloma virus. Similar correlations were later found for
other viruses and kinds of cancer (for example, hepatitis B
increases the risk of hepatocellular carcinoma, and HHV-8,
the risk of Kaposi's sarcoma) [21, 22].
Research performed in the 1960s demonstrated a link
between viral infection and acquisition of cancer cell-like
features by infected cells. In vitro experiments had shown
that expression of viral proteins in normal cells led to their
accelerated proliferation and ability to undergo unlimited
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divisions. Cells infected with oncogenic viruses developed
numerous chromosomal aberrations [23]. First viral onco-
genes were discovered (among them SRC from RSV) [22].
Presence of viruses increases the risk of acquiring cancer,
but is not its direct cause. Incorporation of viral genetic
material into the host genome may lead to oncogenic trans-
formation. Presence of viral proteins changes the phenotype
of host cell. Another mechanism is also possible; integration
of retroviral DNA into genomic DNA can lead to changes in
protein expression. The resulting excess or lack of some
proteins can also be the cause of pathologic lesions [21].
Mutations leading to carcinogenesis may be caused, for
example, by replication errors during cell division or differ-
entiation [19]. The model of treating cancer as a disease of
genes has allowed explaining the link between exposure to
mutagenic agents and morbidity and provided explanation
for increased frequency of some cancers in certain families
as well as for increased incidence among the elderly.
Initially, it was not known which genes play key roles in
carcinogenesis. Researchers supposed that responsible
genes encoded proteins involved in DNA damage repair,
in proliferation, and perhaps genes encoding surface recep-
tors, hormones, etc. To study the role of particular genes in
cancerogenesis, genetically modified mice with inhibited or
overexpressed genes were used. In some experiments, ani-
mals were infected with viruses carrying specific genes or
administered with virally modified cells. If cancer devel-
oped, it was thought that the examined gene played some
role in carcinogenesis. Additional detailed experiments ver-
ified the role of such a gene [24].
The 1980s were a period of intense studies on genes
involved in carcinogenesis. It was noticed that several genes
found in oncoviruses and the counterpart cellular genes
possess identical sequences (e.g., SRC, discovered in avian
DNA) [25]. This meant that viruses can incorporate in their
genome proliferation-stimulating genes of cellular origin
[22, 26].
Structure and function of such genes as TP53, C-MYC,
and C-RAS were discovered. It was found that RAS and
MYC proteins stimulate cell proliferation, whereas TP53 is
involved, among other things, in the control of cellular
response to DNA damage (halting cell division and com-
mitting affected cells to apoptotic pathway). Genes involved
in carcinogenesis were classified as suppressor genes (anti-
oncogenes) and protooncogenes. The latter encode proteins
that stimulate cell divisions. If mutation occurs, these pro-
teins can be expressed continuously, leading to uncontrolled
proliferation. The products of suppressor gene expression,
in turn, inhibit cell division and survival [27].
It is currently thought that the initiation of carcinogenesis
requires simultaneous activation of protooncogenes and in-
activation of suppressor genes. An important role in onco-
genesis is ascribed to mutations in genes encoding proteins
taking part in apoptosis, detection, and repair of damaged
DNA. It has been assumed that cancer results from several
mutations (4–7) in such genes; accumulation of mutations
seems to have priority over the order in which they appear [28].
Carcinogenesis as evolutionary process
Hanahan and Weinberg listed several phenotypic features
and complex processes, distinguishing cancer cells from
normal ones. Among them are: self-sufficiency in terms of
growth signal dependence, insensitivity to growth inhibi-
tors, resistance to apoptosis, limitless replicative potential,
sustained angiogenesis, and ability to invade neighboring
tissues and form metastases [29]. The list of phenotypic
properties of cancer cells has been expanded. Cancer cells
can survive under stress conditions, like hypoxia or nutrient
deprivation. They tolerate DNA damage and presence of
incorrectly folded proteins. Errors during mitosis, such as
incorrect separation of chromosomes between daughter
cells, frequently do not result in apoptosis commitment
[30]. Cancer cells can escape from immune surveillance.
Besides, they are able to transform their microenvironment
in a way that favors tumor progression [31]. All these
features are collectively termed “hallmarks of cancer.”
It was noticed in the 1970s of the twentieth century that
cells forming tumor mass are very heterogenous. They dif-
fer, for example, in their resistance to drugs or sensitivity to
proapoptotic signals. In addition, they become, in time,
more and more aggressive and acquire new features, such
as an ability to form metastases. The model of cancer disease
as a “disease of genes” has taken into account the role of
mutation in disease initiation, but never fully explained this
process. It was concluded that there must be a mechanism
facilitating the emergence and accumulation of successive
alterations. In 1976, Nowell compared neoplastic progression
to evolutionary process [32].
Cancer cells undergo clonal selection. Since starting cells
contain various mutations, also their clones differ between
them. Majority of genome alterations are phenotypically
either neutral or lethal; only few of them favor cell survival.
Such clones start to dominate the growing tumor. Features
giving cells a selection advantage accumulate during tumor
progression. One of such features appearing in cancer cells
is genome instability [33]. Owing to this feature, risk of
successive mutations is increased. Clonal evolution leads to
emergence, from the population of cancer cells, of clones
best adapted to conditions found within a tumor mass [34].
One of the primary factors favoring cell selection is oxygen
and nutrients' deprivation. In the initial stage of tumor growth,
cancer cells form small avascular aggregations of cancer, 0.5–
1 mm in diameter, the so-called in situ tumors [35]. Only cells
using anaerobic glycolysis as main energy source are resistant
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to lack of oxygen and acidic environment and can survive at
this stage. Because of anaerobic glycolysis, the demand for
glucose becomes increased, whereas that for oxygen decreases
(Warburg effect) [36]. Such cells tend to accumulate lesions
that favor survival under unfavorable conditions. Phenotypic
changes can result from the appearance of new mutations or
they can be due to altered gene expression or interference with
signaling pathways [37].
This picture is radically altered when tumors suddenly
acquire the ability to form their own blood vessels (angiogenic
switch). This can be caused by increased amounts of proangio-
genic factors (such as VEGF) secreted by cells or by decreased
production of antiangiogenic molecules. Formation of tumor
vasculature is favored by the presence of other proteins such as
metalloproteinases, degrading extracellular matrix and facili-
tating migration of endothelial cells. Owing to a newly formed
blood vessel network, tumor cells are supplied with nutrients.
This leads to a quick increase of tumor mass which includes
neoplastic cells with proangiogenic phenotype [35].
Functioning of the immune system is an important selection
factor in cancer. Initially, selection favors abnormal cells avoid-
ing immune recognition and destruction, i.e., cells displaying
low expression of cancer-related antigens. At later stages, can-
cer cells not only avoid immune recognition, but they also
produce cytokines and chemokines via which they carry a
specific “talk” with cells forming tumor milieu [38]. Influx
of various cells, such as monocytes, macrophages, den-
dritic cells, and fibroblasts, takes place in tumors. Under
the influence of cytokines and other factors secreted by
these incoming cells, the residing neoplastic cells can
acquire novel properties. Also, the incoming cells can alter
their phenotype. Tumor-associated macrophages (TAMs) start
producing proangiogenic and immunosuppressive factors
such as VEGF, TGF-β, or IL-10. Other type of affected cells
includes fibroblasts. These cancer-associated fibroblasts
(CAFs) also start producing proangiogenic and immunosup-
pressive cytokines and participate in the reconstruction of
extracellular matrix within tumors. The emerging tumor milieu
facilitates tumor progression [39].
Cancer as a disease of stem cells
One of the most recent models of tumorigenesis assumes
that the origin of cancer lies in excessively proliferating and
abnormally altered stem cell. In the 1960s of the last centu-
ry, existence of organ-specific stem cells was demonstrated.
A hierarchy of cancer cells was described 10 years later;
only part of tumor cells is capable of infinite growth, while
the majority has a limited replication potential [40].
Organ-specific stem cells, by assuring tissue renewal,
enable functioning of the whole organism. These cells pos-
sess two defining properties: capability of self-renewal and
ability to differentiate into other cells [41]. Despite a very
efficient system of DNA damage repair, these cells can also
accumulate mutations. Damage to suppressor genes and
protooncogenes can initiate tumorigenic process [40]. Pro-
liferation and differentiation of stem cells are significantly
affected by tumor niche. Changes in tumor microenviron-
ment (e.g., disturbed signaling pathways) can also trigger
excessive proliferation of stem cells [42].
One of the basic features of cancer stem cells (CSCs) is their
ability to form clones in vitro as well as experimental tumors in
vivo (in such trials, human cells are injected into immunodefi-
cient mice). Cells showing the discussed features were found in
numerous kinds of tumors (lung, prostate, breast, and others)
[43]. However, the existence of CSCs is not a proof that
cancers originate from them. Another path leading to the
emergence of cells with the above-described features can in-
volve clonal selection; as a result of accumulated mutations,
part of the differentiated cancer cells acquire the ability to
divide continuously and to further differentiate, i.e., features
characterizing stem cells [41]. CSCs can emerge as well as a
result of dedifferentiation. Epithelial-mesenchymal transition
(EMT) provides a mechanism leading to the appearance of cell
motility and certain features specific for stem cells. Such
transition occurs under the influence of different agents (in-
cluding hypoxia) which may be present in various areas of
neoplastic tumors [44].
Cancer as a systemic disease
Presence of a tumor affects the functioning of entire body;
some researchers believe that the causes of cancer, as well as its
particular phases, require taking a wider look than just that
focusing on processes affecting tumor itself. Even at the time
when cancer was regarded as a disease of cells, many judged
thismodel as oversimplified. The body is not just a “sum” of its
component cells. The direct causes of cancer might lie in
disturbances of homeostasis: cancer is no more a disease of
cells that a traffic jam is a disease of cars [45, 46]. One of the
arguments supporting this concept concerns cases of sponta-
neous healing. According to cell theory, they should not occur
at all; an organism is capable, however, to regain equilibrium
(homeostasis) in some cases. It has also been known that some
cancers (notably breast and prostate tumors) are hormone-
dependent, and therefore, hormonal disorders can be treated
as homeostatic disturbances [46]. It is not clear, however, what
is the direct cause prompting the development of cancer. Since
increased cancer incidence has been noted among people with
impaired immune system (e.g., taking immunosuppressants or
HIV infected), perhaps, this makes immune cells unable to
recognize and destroy cells carrying viral genetic material [47].
Tumors contain, besides abnormal cells, extracellular ma-
trix that differs from that present in normal tissue, both in terms
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of structure and protein composition. Its volume vs. that
of cells is greater than in normal tissues [48]. This results
in altered adhesion of neoplastic cells, expression of
numerous proteins, and signaling pathways. Tumor could
thus be regarded as emanation of incorrect tissue growth
[49, 50].
It has also been pointed out that tumors bear similarities
to unhealing wounds. As during wound healing, tumor cells
are exposed to hypoxia; neovascularization takes place
along with remodeling of extracellular matrix and influx of
immune system cells. As during inflammation, tumor blood
vessels are leakier than those in normal tissues, and serum
proteins infiltrate surrounding tissues. Interstitial pressure in
tumors becomes elevated. Obviously, these processes occur
in tumors in a pathological manner [51].
Summary
Models discussed in the paper illustrate how cancer under-
standing has evolved in time and how various discoveries
have contributed to this evolution. Subsequent models have
reflected medical knowledge attained at corresponding time
points. For example, acquired knowledge of bacteria role in
infectious diseases triggered a search for cancer causes among
microorganisms. This cancer model was later abandoned,
owing to advances in pathology at cellular level. Our perspec-
tive on cancer causes was drastically altered with the elucida-
tion of DNA structure and role. This discovery helped to
explain observations previously seen only as a cause–effect
relationship (e.g., the role of viruses and carcinogens in path-
ogenesis). This cancer concept was subsequently reinforced
by incorporating in it the idea of clonal selection which
explains well the propensity of cancer cells to acquire succes-
sive mutations. Current cancer models attempt to incorporate
the most recent knowledge about stem cells and microenvi-
ronment of immune system cells during cancer progression.
Hopefully, future cancer models will step in the wake of
technological breakthroughs and describe in ever greater de-
tail the most crucial events taking place in cancer cells as well
as whole tumors. In any case, diagnostics and therapy seem to
be clear beneficiaries of future developments in this area.
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